CARTICEL is an autologous cellular product indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft). Manufactured by Genzyme Biosurgery, a pioneer in the field of cartilage repair and cell-based therapies, in a state-of-the-art cell processing facility
, CARTICEL is:
- Created from a patient’s own cartilage.
- Shown to decrease pain and increase function in a challenging patient population.
- Demonstrated durability up to four years in a challenging patient population.
- Can create hyaline-like cartilage.
The world’s first biologic product in orthopaedics, CARTICEL has been in commercial use by surgeons since 1995. In 1997, the FDA granted a Biologic License for CARTICEL. In 2007, the results of the Study of the Treatment of Articular Repair (STAR) were published. STAR was a post-approval study designed to determine the safety and efficacy of CARTICEL in patients who had an inadequate response to a prior surgical repair procedure.
For reimbursement questions, contact a Carticel Care® Coordinator at 800-453-6948, Option #2.
For all other questions, contact a Genzyme representative at 800-453-6948, Option #1.
Read more about patients' experiences with CARTICEL Implantations.
View Case Studies